People · Operator
Named in public records as an officer, director or promoter · active 2011–2011 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Permeon Biologics, Inc. | — | Pharmaceuticals | Seed | $6.0M | $95.1M | 2011 |
Noubar G. Afeyan, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Noubar G. Afeyan, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Edwards | 1 | 8 |
| Keith L. Crandell | 1 | 3 |
| Douglas G. Cole, M.D. | 1 | 1 |
| Douglas Cole, M.D. | 1 | 1 |
| Noubar L. Afeyan, Ph.D. | 1 | 1 |
| Alex Franzusoff | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.